Myopia (nearsightedness) control involves evidence-based treatments such as specialized spectacle lenses, soft contact lenses, and low-dose atropine eye drops to help slow the progression of myopia in children and, in some cases, young adults. Unlike conventional single-vision glasses, which only correct blurred distance vision, myopia control lenses are designed to both provide clear vision and reduce the rate of eye elongation, the main cause of myopia progression.
Myopia usually begins in childhood and often worsens throughout the school years until the late teenage years or early adulthood. Genetics, prolonged near work (such as reading or using digital devices), and limited time spent outdoors are among the major risk factors.
Research has shown that slowing myopia progression is important not only to reduce frequent prescription changes but also to lower the lifetime risk of serious eye diseases associated with high myopia, including retinal detachment, glaucoma, myopic macular degeneration, and certain types of cataracts.
Effective myopia management includes regular eye examinations, early diagnosis, appropriate optical correction, lifestyle modifications (including increased outdoor activity and healthy visual habits), and individualized treatment based on the patient’s age, prescription, and rate of progression.
Early intervention is particularly important in children, as treatment is generally more effective when started soon after myopia develops. The goal of myopia control is not to cure nearsightedness but to preserve long-term eye health by slowing its progression.